Laurus Labs' Q3 net profit soars to ₹252 crore with a 26% revenue increase, driven by strong generics and CDMO demand.

Laurus Labs Ltd. reported a 174% year-on-year increase in consolidated net profit to ₹252 crore for the third quarter of FY26, while revenue from operations grew 26% to ₹1,778 crore. The company's ...

Net Sales at Rs 1,509.42 crore in December 2025 up 19.3% from Rs. 1,265.19 crore in December 2024. Quarterly Net Profit at Rs ...

Laurus Labs is back in focus as the latest research update resets the stock's price target, putting fresh attention on what ...

Laurus Labs posted a manifold increase in net profit to ₹252 crore in the third quarter ended December 31, 2025, compared to ₹92 crore in the corresponding quarter of the previous financial year on ...

Laurus Labs Ltd (BOM:540222) reports robust financial results with significant growth in its generic division and strategic investments in advanced therapies.

Hyderabad: Laurus Bio, a subsidiary of Hyderabad-based biopharma player Laurus Labs Ltd, has secured an equity investment of Rs 120 crore from Eight Roads Ventures and F-Prime Capital. Laurus Labs ...

Laurus Labs API segment is also well set to clock strong growth backed by the company’s increasing focus to diversify into new therapy areas - anti-diabetes and cardiology along with an eye to gain a ...

Compared to the previous quarter, the revenue grew by 20.48% and the profit increased by 226.75%. The Selling, general & administrative expenses rose by 3.97% q-o-q & increased by 19.99% Y-o-Y. The ...

Synergies from RLPL’s acquisition: The acquisition of RLPL would be synergistic for Laurus Labs with benefits likely across the long-term period. Synergies are expected in the area of CDMO business ...